Newsroom

Recent news, statements, and resources

Newsroom

Recent news, statements, and resources

Welcome to The Leukemia & Lymphoma Society Newsroom

Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.

Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society’s Light The Night

March 12, 2024

Text that reads "breaking news" over images of blood cancer cells.

Recent FDA Approval a ‘Great Step in the Right Direction’ for Improving Quality of Life in Blood Cancer Patients

March 11, 2024

Female patient looking hopeful with IV bag

New Report Reveals “Hidden” Patient Costs of Healthcare Consolidation

March 5, 2024

An image with text that reads Breaking News over an image of a myeloma cell.

Latest FDA Approval in Multiple Myeloma May Reduce Treatment Costs, Frequency and Side Effects

February 23, 2024

A scientist injects a liquid substance into a vial.

LLS Experts: CAR T-therapy Benefits Outweigh Risks for Appropriate Patients

February 8, 2024

An image depicting tablets and laptops with text that reads news

The Leukemia & Lymphoma Society and Blood Cancer UK Team Up to Award $4.25M for Research into Ways to Prevent Leukemia

February 5, 2024

Five individuals pose for a photo in front of an Leukemia & Lymphoma Society backdrop.

The Leukemia & Lymphoma Society Honors Five Outstanding Blood Cancer Scientists with 2023 Awards

December 11, 2023

FDA-Approval-Lymphoma

FDA Approves New Drug for the Most Common Form of Leukemia in Adults

December 8, 2023

Several tablets with word "news" displayed on the top of the screen

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

December 8, 2023

Media Requests

For all media-related inquiries and interview requests please email mediarelations@lls.org. An LLS representative will respond as soon as possible.